September 15th

9:00am-9:10am	Opening
	Toshiki Watanabe, IACRLRD president Chair of XXV IACRLRD Symposium 2011 The University of Tokyo, Japan
9:10am-9:40am	John Moloney Memorial Lecture
	Chair: Mitsuaki Yoshida, Cancer Institute of JFCR, Japan
	Luigi Chieco-Bianchi , University of Padova, Italy Contributions of comparative studies of leukemia to advances in cancer research
9:40am-10:40am	Symposium1 Animal Models and Basic Research
	Chairs: Keiya Ozawa , Jichi Medical University, Japan Jacques Ghysdael, Institut Curie, France
	Neal Young , National Heart, Lung, and Blood Institute (NHLBI), USA Marrow failure, telomere attrition, and cancer
	Jacques Ghysdael , Institut Curie, France Dissection of pro-oncogenic pathways in mouse models of lym- phoid leukemia
	Hiromitsu Nakauchi , The Institute of medical Science, The University of Tokyo, Japan Non-myelinating Schwann cells in the bone marrow niche maintain hematopoietic stem cell hibernation through TGF-beta signaling
10:40am-11:00am	Coffee Break
11:00am-12:40pm	Symposium1 Animal Models and Basic Research
	Chairs: Toshio Kitamura , The Institute of medical Science, The University of Tokyo, Japan Riccardo Dalla-Favera , Columbia University, USA
	Stefan K. Bohlander , Philipps University Marburg , Germany Challenges to Leukemia Animal Models in the Era of Next Generation Sequencing
	Cestmir Altaner , Cancer Research Institute, Slovak Academy of Scieinces, Slovakia Human adipose tissue_derived mesenchymal stem cell mediated cytosine deaminase/5-fluorocytosine prodrug therapy in intracra- nial glioblastoma C6 rat model
	John H. Groffen , Childrens Hospital Los Angeles, USA The Philadelphia Translocation: From Molecular Characterization to Mouse Models
	Seishi Ogawa , The University of Tokyo, Japan Whole exome sequencing reveals a novel gene pathway deregulated in myeloid dysplasias
	Toshio Kitamura , The Institute of medical Science, The University of Tokyo, Japan
12:40pm-2:00pm	Two types of C/EBPa mutations collaborate in inducing leukemia in a mouse BMT model. Lunch & Poster display

PROGRAM September 15th

2:00pm-3:20pm	Symposium 2 MDS
	Chairs: Michael Lübbert , University of Freiburg, Medical Center, Germany Yasushi Miyazaki , Nagasaki University Graduate School of Biomedical Sciences, Japan
	Michael Lübbert , University of Freiburg, Medical Center, Germany Epigenetic approaches in MDS/AML treatment
	H.Phillip Koeffler, CEDARS-SINAI Medical Center / UCLA, USA LNK and other aspects of MPD
	Yasushi Miyazaki, Nagasaki University Graduate School of Biomedical Sciences, Japan
	MDS among Atomic Bomb survivors
3:20pm-3:40pm	Jun-ichi Nishimura , Osaka University Graduate School of Medicine, Japan Paroxysmal Nocturnal Hemoglobinuria in Bone Marrow Failure Coffee Break
3:40pm-5:20pm	Symposium 3 MPD/CML
5.40pm-5.20pm	Sponsored by Novartis Pharma K.K.
	Chairs: Andreas Hochhaus , Universitätsklinikum Jena, Germany Arinobu Tojo , The University of Tokyo, Japan
	Stephen David Nimer , Memorial Sloan-Kettering Cancer Center, USA Regulation of PRMTs in myeloid disorders
	Anna Grigorievna Turkina, FSBI Hematology Research Center, Russia Clinical Significance of Additional Chromosomal Abnormalities in Ph-Positive and Ph-Negative Cells in Patients with Cronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors
	Andreas Hochhaus , Universitätsklinikum Jena, Germany Mutations in the BCR-ABL kinase and the second generation TKI
	François Gaudeffroy Guilhot , CIC INSERM 0802, France) The use of smo inhibitors or pegylated form of interferon for tar- geting chronic myeloid stem cells
	Susanne Saußele ,Medizinische Fakultät Mannheim der Universität Heidelberg, Germany Prognostic factors in CML
5:30pm-6:30pm	Welcome Reception

September 16th

9:00am-9:20am	Opening of Jubilee Lectures
	Toshiki Watanabe , IACRLRD president Chair of XXV IACRLRD Symposium 2011 The University of Tokyo, Japan
9:20am-10:00am	Special Lecture 1
	Chair: Toshiki Watanabe, The University of Tokyo, Japan
	Robert C. Gallo, Institute of Human Virology of the University of Maryland School of Medicine, USA Approaching a Successful HIV Preventive Vaccine
10:00am-10:40am	Special Lecture 2
	Chair: Koichi Akashi, Kyushu University, Japan
	Toshio Suda , Keio University, Japan Hematopoietic Stem Cells in the Hypoxic Niches
10:40am-11:00am	Coffee Break
11:00am-11:40am	Special Lecture 3 Chair: Seishi Ogawa, Cancer Genomics Project, University of Tokyo, Japan
	Riccardo Dalla-Favera , Columbia University, USA Oncogenomics of B cell lymphoma
11:40am-noon	Riccardo Dalla-Favera, Columbia University, USA
11:40am-noon noon-1:00pm	Riccardo Dalla-Favera , Columbia University, USA Oncogenomics of B cell lymphoma
	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo
noon-1:00pm	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo Lunch & Poster
noon-1:00pm	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo Lunch & Poster Special Lecture 4
noon-1:00pm	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo Lunch & Poster Special Lecture 4 Chair: Hervé Dombret, University Paris 7 / Saint-Louis Hospital, France Clara D. Bloomfield, Ohio State University , USA Clinical Use of Molecular Markers in Curing Acute Myeloid
noon-1:00pm 1:00pm-1:40pm	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo Lunch & Poster Special Lecture 4 Chair: Hervé Dombret, University Paris 7 / Saint-Louis Hospital, France Clara D. Bloomfield, Ohio State University , USA Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia
noon-1:00pm 1:00pm-1:40pm	Riccardo Dalla-Favera, Columbia University, USA Oncogenomics of B cell lymphoma Travel Award and Group Photo Lunch & Poster Special Lecture 4 Chair: Hervé Dombret, University Paris 7 / Saint-Louis Hospital, France Clara D. Bloomfield, Ohio State University , USA Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia

September 16th

2:40pm-4:00pm	Symposium 4 AML1
	Chairs: David Grimwade , King's College London School of Medicine, United Kingdom Tomoki Naoe , Nagoya University Graduate School of Medicine, Japan
	Zwi N. Berneman , University of Antwerp and Antwerp University Hospital, Belgium Dendritic cell vaccination as a treatment to prevent relapse in acute myeloid leukemia
	Koichi Akashi , Kyushu University, Japan Developmental biology of leukemia stem cells
	Guido Marcucci , The Ohio State Uninversity Med Center/ CCC, USA MicroRNAs in AML: prognostic and therapeutic relevance
	David Grimwade , King's College London School of Medicine, United Kingdom Molecular mechanisms in therapy-related leukaemias
4:00pm-4:20pm	Coffee Break
4:20pm-5:40pm	Symposium 5 AML2
	Chairs: Yuzuru Kanakura , Osaka University Graduate School of Medicine, Japan Clara D. Bloomfield , The Ohio State University , USA
	Tomoki Naoe , Nagoya University Graduate School of Medicine, Japan Targeting the recepter Tyrosinc kinase-STAT axis in acute myeloid leukemia
	Hervé Dombret, University Paris 7 / Saint-Louis Hospital, France Curability of older AML
	Mineo Kurokawa , Graduate School of Medicine, The University of Tokyo, Japan Pathogenetic significance of deregulated transcription factors in acute leukemia
	Christian Thiede , University Hospital Carl Gustav Carus Dresden, Germany Several novel mutations increase the molecular heterogeneity in AML: Impact on the prognostic assessment

September 17th

9:00am-9:20am	Yohei Ito Memorial Lecture
	Chair: Rüdiger Hehlmann, Universität Heidelberg, Germany
	Jan Svoboda , Institute of Molecular Genetics AS CR, Czech Republic Cell fusion and retrovirus rescue from non permissive cells-back- ground and present molecular analysis
9:20am-11:00am	Symposium 6 Lymphoid leukemias:ALL/CLL
	Sponsored by Chugai Parmaceutical Co., Ltd.
	Chairs: Dieter Hoelzer , Onkologikum, Frankfurt am Museumsufer, Germany Claudia D Baldus , Charité, Campus Benjamin Franklin, Germany
	Andrea Biondi, University of Milano-Bicocca; Ospedale S.Gerardo/ Fondazione MBBM, Italy
	Childhood Acute Lymphoblastic Leukemia: where are we?
	Dieter Hoelzer , Onkologikum, Frankfurt am Museumsufer, Germany Current Strategies and Future Options in Adult ALL
	Claudia D Baldus , Charité, Campus Benjamin Franklin, Germany Biology and clinical significance of molecular alterations in adult ALL
	Nora C Heisterkamp , Childrens Hospital Los Angeles, USA Approaches to overcome environmentally-mediated drug resistance in ALL
	Ritsuro Suzuki , Nagoya University, Japan Leukemic presentation of lymphoid malignancy with special refer- ence to NK-cell neoplasms.
11:00am-11:20am	Coffee Break
11:20am-12:40pm	Symposium 7 Lymphomas and Myeloma
	Sponsored by Eizai Co., Ltd.
	Chairs: Masahiro Kizaki , Saitama Medical Center, Saitama Medical University, Japan Anas Younes , MD Anderson, USA
	Masahiro Kizaki , Saitama Medical Center, Saitama Medical University, Japan) New therapeutic approach for multiple myeloma: Development of novel molecular targeting agents
	Robert Baiocchi , The Ohio State University, USA Discovering novel targets for mantle cell lym
	Anas Younes , MD Anderson, USA New treatments in Hodgkin disease
	Kensei Tobinai, National Cancer Center Hospital, Japan Treatment of T/NK-cell lymphoma: Japanese perspective

12:40pm-1:40pm Lunch & Poster

	International Symposium: Progress in HTLV-1 Research
1:40pm-3:20pm	Symposium8 HTLV-1 (1)
	Chairs: David Brighty , The University of Dundee , Scotland Jun-ichi Fujisawa , Kansai Medecal University, Japan
	Luc Willems , FNRS (Belgian National Fund for Scientific Research) at ULg (University of Liège), Belgium Novel antiretroviral therapies for BLV and HTLV
	Renaud Mahieux , Ecole Normale Supérieure de Lyon, France HTLV-1 and HTLV-2 viruses similarities and major differences
	Maria Isabel Thoulouze , Institut Pasteur, France Viral biofilms: a new infectious entity and a new mode of transmis- sion for HTLV-1
	Genoveffa Franchini , National Cancer Institute/National Institute of Health, USA Genetic deterrents for HTLV-1 persistence
	Vincenzo Ciminale , University of Padova, Italy Complex strategies of HTLV-1 expression and control of host cell turnover
3:20pm-3:40pm	Coffee Break
3:40pm-5:00pm	Symposium9 HTLV-1 (2)
	Chairs: Masao Seto , Aichi Cancer Center Research Institute, Japan William Hall , University College Dublin, Ireland
	Charles R. Bangham , Imperial College London , United Kingdom Quantification of HTLV-1 clonality in leukaemia and non-malig- nant infection
	Steve Jacobson, National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA Targeted Therapy for HTLV-1-Associated Myelopathy / Tropical Spastic Paraparesis
	Masao Matsuoka, Institute for Virus Research, Kyoto University, Japan Molecular mechanisms of pathogenesis by HTLV-1
	Hideki Hasegawa , National Institute of Infectious Diseases, Japan Attempt of new treatment in Adult T-cell Leukemia/Lymphoma (ATLL) mouse model
5:00pm-5:20pm	Coffee Break

September 17th

5:20pm-6:40pm Symposium 10 HTLV-1 / ATL

- Chairs: Kunihiro Tsukasaki, Nagasaki University, Japan Renaud Mahieux, Ecole Normale Supérieure de Lyon, France
- Masao Seto, Aichi Cancer Center Research Institute, Japan Frequenct clonal evolution takes palace in ATL patients
- Atae Utsunomiya, Imamura Bun-in Hospital, Japan Recent advances in allogeneic hematopoietic stem cell transplantation for ATL
- **Ali Bazarbachi**, American University of Beirut, Lebanon Can we cure adult T cell leukemia?
- Takashi Ishida, Nagoya City University Graduate School of Medical Sciences, Japan Development of the CCR4-targeted mAb therapy for Adult-T-cell leukemia/lymphoma (ATL)

6:40pm-6:50pm

Closing

Toshiki Watanabe, IACRLRD president Chair of XXV IACRLRD Symposium 2011 The University of Tokyo, Japan